醋酸环丙孕酮与醋酸诺美孕酮对脑膜瘤的联合激素影响:一例病例报告
本文报告一例醋酸环丙孕酮(CPA)相关脑膜瘤病例,患者从CPA更换为醋酸诺美孕酮(NOMAC)后肿瘤继续生长,停用NOMAC后肿瘤缩小。作者认为NOMAC对脑膜瘤可能具有与CPA相似的作用,在脑膜瘤患者中以NOMAC替代CPA的做法应被劝阻,直至获得更多证据。
要点
- CPA相关脑膜瘤患者换用NOMAC后肿瘤继续生长。
- 停用NOMAC后肿瘤出现缩小。
- 作者建议在脑膜瘤患者中不以NOMAC替代CPA。
核心结论
- 作者认为NOMAC对脑膜瘤可能具有与CPA相似的作用。
- 在脑膜瘤患者中以NOMAC替代CPA的做法应被劝阻,直至获得关于NOMAC在该情形中作用的更多证据。
研究设计与样本
- 病例报告,报告一例CPA相关脑膜瘤患者从CPA更换为NOMAC后肿瘤继续生长、停用NOMAC后肿瘤缩小的经过。
主要发现
- CPA相关脑膜瘤患者从CPA更换为NOMAC后肿瘤继续生长。
- 停用NOMAC后肿瘤出现缩小。
临床怎么用
- 作者建议在脑膜瘤患者中不以NOMAC替代CPA,直至获得更多证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cyproterone acetate (CPA) is an antiandrogenic drug which has recently been recognized to promote the occurrence and growth of intracranial meningiomas. Nomegestrol acetate (NOMAC) is a widely used progestin-like drug that could be suggested as an alternative for patients taking CPA. We report a case of CPA-related meningioma for which relay from CPA to NOMAC led to further tumor growth and cessation of NOMAC-induced tumor shrinkage. We suggest NOMAC can have a similar effect than CPA on meningiomas. The use of NOMAC as replacement for CPA in the presence of a meningioma should be discouraged until further evidence becomes available on the role of NOMAC in such instances.
引用
- Champagne PO, Passeri T, Froelich S, et al. Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report. Acta Neurochir (Wien). 2019. PMID: 30666456. doi:10.1007/s00701-018-03782-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。